Patents by Inventor Katie Anderson
Katie Anderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11827700Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making the anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: November 11, 2020Date of Patent: November 28, 2023Assignee: Vitaeris Inc.Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Publication number: 20210246201Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: ApplicationFiled: November 11, 2020Publication date: August 12, 2021Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T.L. Smith
-
Patent number: 11049228Abstract: Devices and methods for controlling display brightness may include receiving a brightness input for controlling a luminance level of at least one display in communication with the computer device. The devices and methods may include receiving high dynamic range (HDR) content and standard dynamic range (SDR) content for presentation on at least one display. The devices and methods may include generating adjusted SDR content by using the brightness input to modify luminance of the SDR content. The devices and methods may include blending the adjusted SDR content and the HDR content together to create a composed framebuffer content with the adjusted SDR content and the HDR content and transmitting the composed framebuffer content for presentation on at least one display.Type: GrantFiled: September 18, 2019Date of Patent: June 29, 2021Assignee: MICROSOFT TECHNOLOGY LICENSING, LLCInventors: Simon Young Tao, David Foster Spruill, Rajat Jain, Katie Anderson
-
Patent number: 10913794Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: November 17, 2017Date of Patent: February 9, 2021Assignee: VITAERIS INC.Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Publication number: 20210027435Abstract: Devices and methods for controlling display brightness may include receiving a brightness input for controlling a luminance level of at least one display in communication with the computer device. The devices and methods may include receiving high dynamic range (HDR) content and standard dynamic range (SDR) content for presentation on at least one display. The devices and methods may include generating adjusted SDR content by using the brightness input to modify luminance of the SDR content. The devices and methods may include blending the adjusted SDR content and the HDR content together to create a composed framebuffer content with the adjusted SDR content and the HDR content and transmitting the composed framebuffer content for presentation on at least one display.Type: ApplicationFiled: September 18, 2019Publication date: January 28, 2021Inventors: Simon Young TAO, David Foster SPRUILL, Rajat JAIN, Katie ANDERSON
-
Patent number: 10800841Abstract: Methods of treating individuals with autoimmune conditions characterized by elevated IL-6 levels comprising the administration of anti-IL-6 antibodies or antibody fragments are provided.Type: GrantFiled: September 13, 2017Date of Patent: October 13, 2020Assignee: VITAERIS, INC.Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, John Latham, Brian R. Kovacevich, Jeffrey T. L. Smith
-
Patent number: 10759853Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: December 21, 2017Date of Patent: September 1, 2020Assignee: Alderbio Holdings LLCInventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Publication number: 20200108140Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or anti-body fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of lift of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (oral risk of developing) an elevated serum C-reactive protein level reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.Type: ApplicationFiled: August 26, 2019Publication date: April 9, 2020Inventors: Leon F. GARCIA-MARTINEZ, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, John A. Latham, Brian R. Kovacevich, Jeffrey T.L. Smith, Mark Litton, Randall Schatzman
-
Publication number: 20200087391Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: ApplicationFiled: May 24, 2019Publication date: March 19, 2020Inventors: Leon F. GARCIA-MARTINEZ, Anne Elisabeth CARVALHO JENSEN, Katie ANDERSON, Benjamin H. DUTZAR, Ethan W. OJALA, Brian R. KOVACEVICH, John A. LATHAM, Jeffrey T.L. SMITH
-
Patent number: 10586509Abstract: Described are examples for adjusting display level properties across multiple displays. One or more ranges of display brightness capability values that are supported by a given display device can be received for multiple display devices. For each of the multiple display devices, at least a portion of display brightness capability values in the one or more ranges of display brightness capability values can be mapped to selectable brightness levels available in an operating system. One of the selectable brightness levels can be determined as selected via the operating system. For each of the multiple display devices, a corresponding display brightness capability value mapped to the one of the selectable brightness levels can be determined and indicated to each of the multiple display devices, such that the multiple display devices may set different display brightness capability value brightness, but the brightness may be perceptually similar across the display devices.Type: GrantFiled: May 30, 2018Date of Patent: March 10, 2020Assignee: MICROSOFT TECHNOLOGY LICENSING, LLCInventors: Katie Anderson, Marcus John Andrews, Jocelyn Berrendonner, Steven E. Lees, Kiran Muthabatulla, Lukasz Konrad Brodzinski, Katherine Blair Huffman, Hideyuki Nagase
-
Publication number: 20200040074Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: ApplicationFiled: March 18, 2019Publication date: February 6, 2020Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T.L. Smith
-
Patent number: 10391169Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.Type: GrantFiled: September 26, 2017Date of Patent: August 27, 2019Assignee: ALDERBIO HOLDINGS LLCInventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, John A. Latham, Brian R. Kovacevich, Jeffrey T. L. Smith, Mark Litton, Randall Schatzman
-
Patent number: 10344086Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: September 11, 2017Date of Patent: July 9, 2019Assignee: ALDERBIO HOLDINGS LLCInventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Publication number: 20190189084Abstract: Described are examples for adjusting display level properties across multiple displays. One or more ranges of display brightness capability values that are supported by a given display device can be received for multiple display devices. For each of the multiple display devices, at least a portion of display brightness capability values in the one or more ranges of display brightness capability values can be mapped to selectable brightness levels available in an operating system. One of the selectable brightness levels can be determined as selected via the operating system. For each of the multiple display devices, a corresponding display brightness capability value mapped to the one of the selectable brightness levels can be determined and indicated to each of the multiple display devices, such that the multiple display devices may set different display brightness capability value brightness, but the brightness may be perceptually similar across the display devices.Type: ApplicationFiled: May 30, 2018Publication date: June 20, 2019Inventors: Katie ANDERSON, Marcus John ANDREWS, Jocelyn BERRENDONNER, Steven E. LEES, Kiran MUTHABATULLA, Lukasz Konrad BRODZINSKI, Katherine Blair HUFFMAN, Hideyuki NAGASE
-
Publication number: 20190085066Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for HGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-HGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-HGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-HGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with HGF.Type: ApplicationFiled: October 12, 2018Publication date: March 21, 2019Inventors: Benjamin H. Dutzar, Katie Anderson, Brian R. Kovacevich, Andrew L. Feldhaus, John Latham, Leon F. Garcia-Martinez
-
Patent number: 10233239Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making the anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: August 4, 2017Date of Patent: March 19, 2019Assignee: ALDERBIO HOLDINGS LLCInventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Publication number: 20180371079Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: ApplicationFiled: December 21, 2017Publication date: December 27, 2018Inventors: Leon F. GARCIA-MARTINEZ, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T.L. Smith
-
Patent number: 10100108Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for HGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-HGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-HGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-HGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with HGF.Type: GrantFiled: September 27, 2016Date of Patent: October 16, 2018Assignee: ALDERBIO HOLDINGS LLCInventors: Benjamin H. Dutzar, Katie Anderson, Brian R. Kovacevich, Andrew L. Feldhaus, John Latham, Leon F. Garcia-Martinez
-
Publication number: 20180201675Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: ApplicationFiled: November 17, 2017Publication date: July 19, 2018Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T.L. Smith
-
Publication number: 20180201668Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab 1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other cogulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.Type: ApplicationFiled: December 19, 2017Publication date: July 19, 2018Inventors: Leon F. GARCIA-MARTINEZ, Anne Elisabeth CARVALHO JENSEN, Katie ANDERSON, Benjamin H. DUTZAR, Ethan W. OJALA, Brian R. KOVACEVICH, John A. LATHAM, Jeffrey T.L. SMITH